Press release
Medulloblastoma Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore our latest breakthroughs in Medulloblastoma Research. Learn more about our innovative pipeline today! @ Medulloblastoma Pipeline Outlook [https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Medulloblastoma Pipeline Report
* In June 2025, John Yu announced a study is to examine the use of a single dose of tozuleristide (24 or 36 mg) and the Canvas imaging system during surgical resection of primary central nervous system (CNS) tumors: Primary gadolinium enhancing (high grade) CNS tumors, primary non-gadolinium enhancing CNS tumors, and primary vestibular schwannoma.
* In June 2025, Hoffmann-La Roche conducted a Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
* DelveInsight's Medulloblastoma pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Medulloblastoma treatment.
* The leading Medulloblastoma Companies such as Biodexa Pharmaceuticals, Valent Technologies LLC, Novartis Oncology, Sun Pharmaceutical Industries, Chimerix, Curis and others.
* Promising Medulloblastoma Pipeline Therapies such as CX 4945, LDE225, TMZ, Nifurtimox, Cyclophosphamide, Topotecan, Irinotecan, Temozolomide and others.
Stay informed about the cutting-edge advancements in Medulloblastoma treatments. Download for updates and be a part of the revolution in oncology care @ Medulloblastoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Medulloblastoma Emerging Drugs Profile
* MTX110: Biodexa Pharmaceuticals
MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl--cyclodextrin (HPBCD) that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak Registered ) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG and recurrent medulloblastoma and preclinically for treatment of glioblastoma. MTX110 is delivered directly into and around the patient's tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell lines. Currently the drug is in Phase I stage of development for the treatment of medulloblstoma.
The Medulloblastoma Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Medulloblastoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Medulloblastoma Treatment.
* Medulloblastoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Medulloblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Medulloblastoma market.
Learn more about Medulloblastoma Drugs opportunities in our groundbreaking Medulloblastoma research and development projects @ Medulloblastoma Unmet Needs [https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Medulloblastoma Companies
Biodexa Pharmaceuticals, Valent Technologies LLC, Novartis Oncology, Sun Pharmaceutical Industries, Chimerix, Curis and others.
Medulloblastoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Medulloblastoma Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Medulloblastoma treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Medulloblastoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Medulloblastoma Pipeline Report
* Coverage- Global
* Medulloblastoma Companies- Biodexa Pharmaceuticals, Valent Technologies LLC, Novartis Oncology, Sun Pharmaceutical Industries, Chimerix, Curis and others.
* Medulloblastoma Pipeline Therapies- CX 4945, LDE225, TMZ, Nifurtimox, Cyclophosphamide, Topotecan, Irinotecan, Temozolomide and others.
* Medulloblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Medulloblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Medulloblastoma Pipeline on our website @ Medulloblastoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Medulloblastoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Medulloblastoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* MTX110: Biodexa Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Medulloblastoma Key Companies
* Medulloblastoma Key Products
* Medulloblastoma- Unmet Needs
* Medulloblastoma- Market Drivers and Barriers
* Medulloblastoma- Future Perspectives and Conclusion
* Medulloblastoma Analyst Views
* Medulloblastoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=medulloblastoma-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medulloblastoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Medulloblastoma Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4096647 • Views: …
More Releases from ABNewswire
VagiThera Bringing Premium At-Home Ultrasound Skincare to Life
Image: https://www.abnewswire.com/upload/2025/08/67bb95286bac3d1e681743233661f729.jpg
Attibe Beauty is proud to announce the Indiegogo launch of VagiThera [https://www.vagithera.com/], a premium at-home wellness device designed to empower women with precise, safe, and convenient skincare for delicate areas. Combining 360 degrees rotating micro-focused ultrasound (MFU) technology with ergonomic, wireless design, VagiThera brings professional-grade care into the comfort of home.
Developed over 8 years in collaboration with certified Korean wellness technology experts, VagiThera targets sensitive zones often left untouched…
New Book by Dr. Pietro Emanuele Garbelli Charts a Bold Path for Physicians in th …
As artificial intelligence, robotics, and automation revolutionize modern healthcare, the question looms: What will be the role of the doctor in this new era?
In his groundbreaking new book, The Doctor's Future (Balboa Press, ISBN: 9798765257791), Dr. Pietro Emanuele Garbelli answers with a clear, actionable roadmap for physicians and healthcare leaders to not only adapt but lead.
Drawing on over two decades of frontline medical experience and high-level consulting, Dr. Garbelli introduces…
Award Winning Author Tony Jeton Selimi Releases New Book - Climb Greater Heights
New Book Empowers Entrepreneurs and Leaders to Scale Their Business, Influence, and Legacy
Internationally recognized transformational life strategist and business growth expert Tony Jeton Selimi announces the release of his latest book, Climb Greater Heights, a powerful blueprint for ambitious entrepreneurs, seasoned business owners, and driven leaders ready to break through growth barriers and lead with purpose.
More than a business manual, Climb Greater Heights blends proven strategies, mindset shifts, and real-world…
Kindred Realtors: Delivering Premier Results for Bay Area Buyers, Sellers & Inve …
Bay Area, CA - In the dynamic world of Bay Area real estate, choosing the right partner is essential. With nearly $200 million in closed sales and a combined 25 years of experience, Kindred Realty, a father-daughter family team, sets the standard for success among buyers, sellers, and investors throughout Oakland, Berkeley, the East Bay and surrounding communities. The team's dedication to personalized service and market knowledge has earned them…
More Releases for Medulloblastoma
Medulloblastoma Market 2025-2034 Business Outlook, Critical Insight and Growth
Introduction
Medulloblastoma is a rare and aggressive brain tumor that primarily affects children, originating in the cerebellum. Though it accounts for a small percentage of all childhood cancers, medulloblastoma is the most common malignant brain tumor in pediatric patients. While survival rates for medulloblastoma have improved due to advances in surgery, radiation, and chemotherapy, the prognosis for high-risk patients remains poor, and the long-term side effects of treatment can significantly impact…
Strong Growth Ahead: Medulloblastoma Drug Market Size To Grow At Arecord 8.6% Ca …
"Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How Big Is the Medulloblastoma Drug Market Size Expected to Be by 2034?
The market for medulloblastoma medication has demonstrated substantial growth in recent times. The market is projected to escalate from $2.80 billion in 2024 to $3.06 billion in 2025, indicating a compound annual growth rate (CAGR) of 9.0%. This growth observed in…
Key Trends Shaping the Future Medulloblastoma Drug Market From 2025-2034: Advanc …
What industry-specific factors are fueling the growth of the medulloblastoma drug market?
The medical sector anticipates an escalation in the medulloblastoma drug market due to the increasing prevalence of brain tumors. Brain tumors, which constitute of unusual cell growth in the brain or the spinal canal, can be either benign or malignant and have the potential to obstruct brain function. Enhanced detection techniques, an aging demographic, environmental influences, heightened awareness, and…
Medulloblastoma Market Report 2023-2033 | Industry Size, Analysis and Latest Ins …
Market Overview:
The 7 major medulloblastoma markets are expected to exhibit a CAGR of 6.3% during 2023-2033.
The report offers a comprehensive analysis of the medulloblastoma market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions.…
Rich Insights into the Medulloblastoma Pipeline and Clinical Trial Analysis Feat …
DelveInsight's, "Medulloblastoma Pipeline Insight, 2023," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Medulloblastoma pipeline landscape. It covers the Medulloblastoma pipeline drug profiles, including Medulloblastoma clinical trials and nonclinical stage products. It also covers the Medulloblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Medulloblastoma Emerging drugs, the Medulloblastoma…
Medulloblastoma Drug Market Industry Size, Status and Outlook, Competitive Lands …
The report “Global Medulloblastoma Drug Market Growth 2021-2028” from Databridge Market Research includes data and information about market structure and size. The purpose of this research is to give market knowledge and strategic insights to assist in decision making, making informed investment decisions, and identifying potential growth opportunities.
Download Free Sample Report: To Know The Impact Of COVID-19 On This Industry @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-medulloblastoma-drug-market
The Global Medulloblastoma Drug Market market report also indicates…
